トリラシクリブ

トリラシクリブ 化学特性,用途語,生産方法

• 効能

  抗悪性腫瘍薬, サイクリン依存性キナーゼ(CDK)阻害薬

• 使用

  Trilaciclib is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.

• brand name

  Cosela^TM

• 合成

  The synthesis of trilaciclib is as follows:
  Intermediate 2 (21.1 g, 70 mmol) and 1-methyl-4-(6-aminopyridin-3-yl)piperazine (13.4 g, 70 mmol) were added to a 100 mL vacuum tube and reacted at 230° C. for 3 h.After the reaction, 300 mL of ethyl acetate was added, washed with water (120 mL) and saturated brine (120 mL) successively, dried with anhydrous sodium sulfate and filtered, the obtained solution was evaporated under reduced pressure to remove the solvent, and the obtained residue was recrystallized with ethanol, 27.5 g of Trilaciclib was obtained with a purity of 99% and a yield of 88%.
  
  

• 貯蔵

  Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).

トリラシクリブ 生産企業

Global(77)Suppliers

1374743-00-6, トリラシクリブ キーワード